Monopar Therapeutics Inc. (MNPR) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-12.18M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.68× | Operating cash flow / net income. Period ending 2026-06-30. $-12.18M ÷ $-17.84M ≈ 0.68× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -12.18M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -17.84M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-12.18M | (m) | (m) | (m) | (m) | $-17.84M | (m) | (m) | (m) | 0.68× |
| 2026-03-31 | (m) | (m) | $-10.01M | (m) | (m) | (m) | (m) | $-14.99M | (m) | (m) | (m) | 0.67× |
| 2025-12-31 | (m) | (m) | $-12.20M | (m) | (m) | $0.00 | (m) | $-13.72M | (m) | (m) | (m) | 0.89× |
| 2025-09-30 | (m) | (m) | $-10.83M | (m) | (m) | (m) | (m) | $-19.44M | (m) | (m) | (m) | 0.56× |
| 2025-06-30 | (m) | (m) | $-9.81M | (m) | (m) | (m) | (m) | $-17.31M | (m) | (m) | (m) | 0.57× |
| 2025-03-31 | (m) | (m) | $-10.41M | (m) | (m) | (m) | (m) | $-16.57M | (m) | (m) | (m) | 0.63× |
| 2024-12-31 | (m) | (m) | $-6.40M | (m) | (m) | $0.00 | (m) | $-15.59M | (m) | (m) | (m) | 0.41× |
| 2024-09-30 | (m) | (m) | $-5.95M | (m) | (m) | (m) | (m) | $-6.47M | (m) | (m) | (m) | 0.92× |
| 2024-06-30 | (m) | (m) | $-6.82M | (m) | (m) | (m) | (m) | $-7.12M | (m) | (m) | (m) | 0.96× |
| 2024-03-31 | (m) | (m) | $-7.24M | (m) | (m) | (m) | (m) | $-7.61M | (m) | (m) | (m) | 0.95× |
| 2023-12-31 | (m) | (m) | $-7.86M | (m) | (m) | (m) | (m) | $-8.40M | (m) | (m) | (m) | 0.94× |
| 2023-09-30 | (m) | (m) | $-7.61M | (m) | (m) | (m) | (m) | $-9.48M | (m) | (m) | (m) | 0.80× |
| 2023-06-30 | (m) | (m) | $-7.82M | (m) | (m) | (m) | (m) | $-9.93M | (m) | (m) | (m) | 0.79× |
| 2023-03-31 | (m) | (m) | $-7.03M | (m) | (m) | (m) | (m) | $-10.49M | (m) | (m) | (m) | 0.67× |
| 2022-12-31 | (m) | (m) | $-7.23M | (m) | (m) | (m) | (m) | $-10.52M | (m) | (m) | (m) | 0.69× |
| 2022-09-30 | (m) | (m) | $6.68M | (m) | (m) | (m) | (m) | $-10.30M | (m) | (m) | (m) | -0.65× |
| 2022-06-30 | (m) | (m) | $6.88M | (m) | (m) | (m) | (m) | $-10.36M | (m) | (m) | (m) | -0.66× |
| 2022-03-31 | (m) | (m) | $6.79M | (m) | (m) | (m) | (m) | $-9.68M | (m) | (m) | (m) | -0.70× |
| 2021-12-31 | (m) | (m) | $7.32M | (m) | (m) | (m) | (m) | $-9.10M | (m) | (m) | (m) | -0.80× |
| 2021-09-30 | (m) | (m) | $-6.53M | (m) | (m) | (m) | (m) | $-8.55M | (m) | (m) | (m) | 0.76× |
| 2021-06-30 | (m) | (m) | $-5.89M | (m) | (m) | (m) | (m) | $-7.73M | (m) | (m) | (m) | 0.76× |
| 2021-03-31 | (m) | (m) | $-5.47M | (m) | (m) | (m) | (m) | $-7.10M | (m) | (m) | (m) | 0.77× |
| 2020-12-31 | (m) | (m) | $-4.66M | (m) | (m) | (m) | (m) | $-6.30M | (m) | (m) | (m) | 0.74× |
| 2020-09-30 | (m) | (m) | $-4.09M | (m) | (m) | (m) | (m) | $-5.38M | (m) | (m) | (m) | 0.76× |
| 2020-06-30 | (m) | (m) | $-3.40M | (m) | (m) | (m) | (m) | $-4.48M | (m) | (m) | (m) | 0.76× |
| 2020-03-31 | (m) | (m) | $-3.15M | (m) | (m) | (m) | (m) | $-3.94M | (m) | (m) | (m) | 0.80× |
| 2019-12-31 | (m) | (m) | $-3.02M | (m) | (m) | $0.00 | (m) | $-4.22M | (m) | (m) | (m) | 0.71× |
| 2019-09-30 | (m) | (m) | $-3.07M | (m) | (m) | $0.00 | (m) | $-3.91M | (m) | (m) | (m) | 0.79× |
| 2019-06-30 | (m) | (m) | $-3.06M | (m) | (m) | $0.00 | (m) | $-3.81M | (m) | (m) | (m) | 0.80× |
| 2019-03-31 | (m) | (m) | $-3.07M | (m) | (m) | $0.00 | (m) | $-3.73M | (m) | (m) | (m) | 0.82× |
| 2018-12-31 | (m) | (m) | $-2.89M | (m) | (m) | $0.00 | (m) | $-3.23M | (m) | (m) | (m) | 0.89× |
| 2018-09-30 | (m) | (m) | $-2.98M | (m) | (m) | $0.00 | (m) | $-3.05M | (m) | (m) | (m) | 0.98× |
| 2018-06-30 | (m) | (m) | $-3.57M | (m) | (m) | $0.00 | (m) | $-17.29M | (m) | (m) | (m) | 0.21× |
| 2018-03-31 | (m) | (m) | $-3.12M | (m) | (m) | $0.00 | (m) | $-17.06M | (m) | (m) | (m) | 0.18× |
| 2017-12-31 | (m) | (m) | $-2.63M | (m) | (m) | $0.00 | (m) | $-16.55M | (m) | (m) | (m) | 0.16× |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $-1.19M | (m) | (m) | $0.00 | (m) | $-1.19M | (m) | (m) | (m) | 1.01× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |